Literature DB >> 2419383

Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study.

G Hedlin, V Graff-Lonnevig, H Heilborn, G Lilja, K Norrlind, K O Pegelow, B Sundin, H Løwenstein.   

Abstract

The effects of immunotherapy on the skin prick test, allergen-specific IgE, and IgG in 39 patients (19 adults and 20 children), treated with partially purified cat- or dog-dander extracts or placebo for 1 year, were studied by use of a double-blind protocol. IgG levels were measured by three different assays: IgG RAST, IgG4 RAST, and Staph A IgG1, 2, and 4. The skin prick test reaction decreased continuously in the allergen-treated patients, the decrease being the first sign of an immunologic effect of the therapy. Allergen-specific IgE levels increased during the first 9 months in both children and adults. The RAST activity during the last 3 months continued to rise for the children, whereas it declined for the adults. IgG levels measured by all three methods demonstrated an increase in the allergen-treated patients and no increase in the placebo-treated patients. The children developed higher values on IgG RAST and IgG4 RAST than the adults. IgG RAST correlated negatively with IgE levels in the cat allergen-treated group. No correlation between skin prick test results, IgE levels, and IgG levels was found, nor was there any correlation between these parameters and the patients' own subjective evaluation or the allergen bronchial challenge test. In summary, the expected change in skin prick test reaction and allergen-specific IgE and IgG levels was found. The children tended to be more immunologically active than the adults.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419383     DOI: 10.1016/0091-6749(86)90184-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  Immunological response to immunotherapy for immediate hypersensitivity: clinical relevance.

Authors:  R Tamir; A I Pick
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

2.  Fel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4+CD25-Foxp3+ Treg cells.

Authors:  Yechun Pei; Shuang Geng; Lin Liu; Fengxiang Yan; Hong Guan; Jian Hou; Yongfu Chen; Bin Wang; Xiaorong An
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

3.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.

Authors:  Nicole Schmitz; Klaus Dietmeier; Monika Bauer; Melanie Maudrich; Stefan Utzinger; Simone Muntwiler; Philippe Saudan; Martin F Bachmann
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

Review 4.  Accelerated immunotherapy schedules.

Authors:  Christopher W Calabria
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 5.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 6.  Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party.

Authors:  A J Frew
Journal:  BMJ       Date:  1993-10-09

Review 7.  Asthma in children and adolescents: a comprehensive approach to diagnosis and management.

Authors:  Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.